Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS)

NCT03037164 is registered in ClinicalTrials.gov with Cerus Corporation as lead sponsor.

NCT NCT03037164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03037164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS)
Lead sponsor
Cerus Corporation
Phase
Phase 3
Overall status
Completed
Start date
May 10, 2017
Completion date
July 6, 2026
Enrollment
692 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

anemia